Christophe Schmitt - Concepedia

Author

Christophe Schmitt

Roche (Switzerland)ORCID

Also Known As

Anne Charoin-Pannier, C Schmitt, C. Schmitt, Christophe Schmitt

Publications

5.1K

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)University of Bonn Hospital Universitario La Paz Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Children's Hospital of Los Angeles

About

Christophe Schmitt is an author at Roche (Switzerland) specializing in medicine, hematology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	1.3K
2	Health Sciences	4	4	718
3	Allergy	1	1	76
4	Diabetes	1	1	316
5	Endocrinology	1	1	316

Christophe Schmitt

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
Emicizumab Prophylaxis in Hemophilia A with Inhibitors Johannes Oldenburg, Johnny Mahlangu, Benjamin Kim, New England Journal of Medicine	2017	1K
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors Johnny Mahlangu, Johannes Oldenburg, Ido Paz‐Priel, New England Journal of Medicine	2018	708
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study Steven W. Pipe, Midori Shima, Michaela Lehle, The Lancet Haematology Haven 4HematologyNon-randomised Phase 3Emicizumab ProphylaxisMedicine	2019	373
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors Guy Young, Ri Liesner, Tiffany Chang, Blood	2019	361
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes Juan P. Frías, Edward J. Bastyr, Louis Vignati, Cell Metabolism Molecular PharmacologyMetabolic SyndromeSustained EffectsDiabetes ManagementMedicine	2017	316
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies Michael U. Callaghan, Claude Négrier, Ido Paz‐Priel, Blood ThrombosisAntibioticsPediatric HematologyBleed RateHematology	2020	270
Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis Christophe Schmitt, Bernd Kuhn, X Zhang, Clinical Pharmacology & Therapeutics	2011	250
Integration of in Vitro Data into Allometric Scaling to Predict Hepatic Metabolic Clearance in Man: Application to 10 Extensively Metabolized Drugs T. Lave, Sylvie Dupin, Christophe Schmitt, Journal of Pharmaceutical Sciences	1997	179
The Use of Human Hepatocytes to Select Compounds Based on Their Expected Hepatic Extraction Ratios in Humans T. Lave, Sylvie Dupin, Christophe Schmitt, Pharmaceutical Research	1997	105
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study Christophe Schmitt, Joanne I. Adamkewicz, Jin Xu, Thrombosis and Haemostasis	2020	91

Page 1